Alight Expands GLP-1 Therapy Access via eMed Partnership
Event summary
- Alight added eMed to its Partner Network to expand employer access to GLP-1 therapies.
- GLP-1 medication use among U.S. adults rose from 3% in 2024 to 11% in 2026, per Gallup.
- The partnership aims to improve treatment adherence and manage healthcare costs for employers.
- Alight serves over 30 million people through its benefits administration platform.
The big picture
The partnership reflects the growing demand for employer-sponsored solutions addressing chronic condition management and rising healthcare costs. With GLP-1 therapies gaining popularity, this collaboration positions Alight to capitalize on a critical workforce health trend. The integration of eMed's platform into Alight's ecosystem could set a new standard for benefits administration in managing population health.
What we're watching
- Adoption Pace
- How quickly employers will integrate GLP-1 programs into their benefits strategies.
- Cost Control
- Whether the partnership can effectively reduce avoidable healthcare spend for employers.
- Market Differentiation
- The extent to which Alight's expanded health ecosystem will set it apart from competitors.
Related topics